PHARMACOKINETICS AND BIOAVAILABILITY OF MEDROXYPROGESTERONE ACETATE IN THE DOG AND THE RAT

被引:3
|
作者
SMITH, D [1 ]
ENEVER, R [1 ]
DEY, M [1 ]
LATTA, D [1 ]
WEIERSTALL, R [1 ]
机构
[1] WYETH AYERST RES,DRUG SAFETY EVALUAT,CHAZY,NY 12921
关键词
MEDROXYPROGESTERONE ACETATE; PHARMACOKINETICS; BIOAVAILABILITY; WEIBULL FUNCTION;
D O I
10.1002/bdd.2510140407
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Medroxyprogesterone acetate (MPA) has been administered to rats and dogs. Dogs received single oral doses of 2 - 5, 5, and 10 mg MPA and a single intravenous dose of 1 mg MPA. Rats received single oral doses of 0 . 2, 1, 5, and 20 mg kg-1 MPA and multiple oral doses (14 daily doses) of 0 . 2, 5, and 20 mg kg-1 MPA. Dog plasma MPA levels from the intravenous dose were characterized by a triexponential decay with disposition half-lives of 0 - 3, 1.8, and 21.6 h. A Loo-Riegelman analysis of the dog plasma MPA levels from oral doses indicated absorption was not a simple first-order process. The Weibull Function was used to characterize the absorption kinetics of MPA. The oral absorption of MPA in dogs appears to be dose-linear over the dosage range studied, and the absolute bioavailability was estimated at 27 per cent. Rat plasma MPA levels from single and multiple oral doses were analyzed by a non-compartmental approach. AUC and C(max) values were not dose-linear over the dosage range studied; indicative of the self-induced metabolism of MPA. Exposure of similar dosages of MPA to both the rat and the dog resulted in similar plasma profiles and pharmacokinetics.
引用
收藏
页码:341 / 355
页数:15
相关论文
共 50 条
  • [21] A FURTHER CASE OF MEDROXYPROGESTERONE ACETATE ASSOCIATED WITH CALCINOSIS CIRCUMSCRIPTA IN THE DOG
    GINEL, PJ
    LOPEZ, R
    RIVAS, R
    PEREZ, J
    MOZOS, E
    VETERINARY RECORD, 1995, 136 (02) : 44 - 45
  • [22] COMPARATIVE PHARMACOKINETICS OF MEDROXYPROGESTERONE ACETATE ADMINISTERED BY ORAL AND INTRAMUSCULAR ROUTES
    SALIMTSCHIK, M
    MOURIDSEN, HT
    LOEBER, J
    JOHANSSON, E
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1980, 4 (04) : 267 - 269
  • [23] MEDROXYPROGESTERONE ACETATE PLASMA PHARMACOKINETICS AFTER INTRAVENOUS ADMINISTRATION IN RABBITS
    PANNUTI, F
    CAMAGGI, CM
    STROCCHI, E
    COMPARSI, R
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1987, 19 (04) : 311 - 314
  • [24] PHARMACOKINETICS OF SUBCUTANEOUS DEPOT MEDROXYPROGESTERONE ACETATE INJECTED IN THE UPPER ARM
    Halpern, V
    Combes, S.
    Weiner, D.
    Archer, D.
    CONTRACEPTION, 2012, 86 (03) : 315 - 315
  • [25] PHARMACOKINETICS AND BIOAVAILABILITY OF PYRENE IN THE RAT
    WITHEY, JR
    LAW, FCP
    ENDRENYI, L
    JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH, 1991, 32 (04): : 429 - 447
  • [26] PHARMACOKINETICS AND BIOAVAILABILITY OF DICLOFENAC IN THE RAT
    PERISRIBERA, JE
    TORRESMOLINA, F
    GARCIACARBONELL, MC
    ARISTORENA, JC
    PLADELFINA, JM
    JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1991, 19 (06): : 647 - 665
  • [27] MEDROXYPROGESTERONE ACETATE PHARMACOKINETICS FOLLOWING ORAL HIGH-DOSE ADMINISTRATION IN HUMANS - A BIOAVAILABILITY EVALUATION OF A NEW MPA TABLET FORMULATION
    JOHANSSON, EDB
    JOHANSEN, PB
    RASMUSSEN, SN
    ACTA PHARMACOLOGICA ET TOXICOLOGICA, 1986, 58 (05): : 311 - 317
  • [28] Binding specificity of medroxyprogesterone acetate and proligestone for the progesterone and glucocorticoid receptor in the dog
    Selman, PJ
    Wolfswinkel, J
    Mol, JA
    STEROIDS, 1996, 61 (03) : 133 - 137
  • [29] PHARMACOKINETICS AND METABOLISM OF MEDROXYPROGESTERONE ACETATE IN PATIENTS WITH ADVANCED BREAST-CANCER
    UTAAKER, E
    LUNDGREN, S
    KVINNSLAND, S
    AAKVAAG, A
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1988, 31 (4A): : 437 - 441
  • [30] MEDROXYPROGESTERONE ACETATE METABOLISM BY CULTURED RAT CECAL CONTENTS
    MARTIN, F
    ADLERCREUTZ, H
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1978, 9 (09): : 823 - 823